Journal article
Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus
Abstract
BACKGROUND: High costs of direct-acting antivirals (DAAs) have led health-care insurers to limit access worldwide. Using a natural experiment, we evaluated the impact of removing fibrosis stage restrictions on hepatitis C (HCV) treatment initiation rates among people living with human immunodeficiency virus (HIV), and then examined who was left to be treated.
METHODS: Using data from the Canadian HIV-HCV Coinfection Cohort, we applied a …
Authors
Saeed S; Strumpf E; Moodie EEM; Wong L; Cox J; Walmsley S; Tyndall M; Cooper C; Conway B; Hull M
Journal
Clinical Infectious Diseases, Vol. 71, No. 2, pp. 363–371
Publisher
Oxford University Press (OUP)
Publication Date
July 11, 2020
DOI
10.1093/cid/ciz833
ISSN
1058-4838